Cellphire Therapeutics

Cellphire Therapeutics is pioneering the development of stabilized platelet biologics to solve critical shortages and logistical challenges associated with traditional platelet transfusions. The company has two primary clinical-stage assets: CLPH-511 (cryopreserved platelets) and the FPH platform (freeze-dried platelet-derived hemostats like Thrombosomes®), both in Phase 2 studies for acute bleeding. Its first commercial product, StablePlate RX® Canine, is marketed through its veterinary subsidiary, BodeVet®, providing an early revenue stream. Cellphire aims to address a significant unmet need in both military and civilian settings where hemorrhage is a leading cause of preventable death.

Proprietary platforms for stabilizing human platelets via cryopreservation (extended frozen shelf-life) and freeze-drying/lyophilization (room-temperature stable platelet-derived hemostatic powder).

Competition includes other companies developing platelet substitutes, synthetic hemostats, and stabilized blood products, but Cellphire's focus on actual platelet-derived biologics with long-term stability is distinctive. Its lead in clinical development, particularly with positive efficacy data for a cryopreserved platelet, positions it as a potential first-to-market in this niche. Traditional surgical hemostats and plasma-derived products address different aspects of the bleeding problem.